News | Heart Valve Technology | January 25, 2017

Edwards Lifesciences Completes Acquisition of Valtech Cardio

Final cost of acquisition comes to $340 million

Edwards Lifesciences, completes acquisition, Valtech Cardio

January 25, 2017 — Edwards Lifesciences Corp. announced that it has closed its acquisition of Valtech Cardio Ltd., developer of the Cardioband System for transcatheter repair of the mitral and tricuspid valves. Edwards announced in November that it had signed an agreement to acquire Valtech.

Under the terms of the merger agreement, Edwards paid $340 million in stock and cash for Valtech at closing, subject to typical adjustments. In addition, there is the potential for up to $350 million in pre-specified milestone-driven payments over the next 10 years. Edwards' financial guidance provided at its Investor Conference in December incorporated the expected financial impact of the transaction in 2017.

The Cardioband System is not approved for sale in the United States. The mitral application of the Cardioband System has received CE Mark in Europe.

Read the article “Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation,” which is about use of the Cardsioband system.

For more information: www.edwards.com


Related Content

News | Heart Valve Technology

August 2, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced that the ...

Home August 02, 2023
Home
News | Heart Valve Technology

July 31, 2023 — Today, the U.S. Food and Drug Administration (FDA) is providing an update to the February 27, 2023 ...

Home July 31, 2023
Home
News | Heart Valve Technology

July 24, 2023 — Allegheny General Hospital (AGH), the flagship academic medical center of Allegheny Health Network (AHN) ...

Home July 24, 2023
Home
News | Heart Valve Technology

June 6, 2023 — According to a news release issued by the U.S. Food and Drug Administration (FDA), Abiomed has recalled ...

Home June 06, 2023
Home
News | Heart Valve Technology

May 9, 2023 — Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of ...

Home May 09, 2023
Home
News | Heart Valve Technology

February 28, 2023 — On Feb. 27, the U.S. Food and Drug Administration (FDA) issued a Letter to Health Care Providers to ...

Home February 28, 2023
Home
News | Heart Valve Technology

January 23, 2023 — Leakage of the mitral valve due to degenerative prolapse is a common condition known as primary ...

Home January 23, 2023
Home
News | Heart Valve Technology

January 2, 2023 — The U.S. Food and Drug Administration (FDA) has given the approval to market to The Edwards ...

Home January 02, 2023
Home
News | Heart Valve Technology

December 29, 2022 — The Smidt Heart Institute at Cedars-Sinai was named a Mitral Valve Repair Reference Center, a ...

Home December 29, 2022
Home
Subscribe Now